- Home
- JXJT vs ONVO Comparison
JXJT vs ONVO Comparison
Compare JXJT & ONVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JXJT
- ONVO
- Stock Information
- Founded
- JXJT 2012
- ONVO 2007
- Country
- JXJT China
- ONVO United States
- Employees
- JXJT N/A
- ONVO N/A
- Industry
- JXJT Apparel
- ONVO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- JXJT Consumer Staples
- ONVO Health Care
- Exchange
- JXJT Nasdaq
- ONVO Nasdaq
- Market Cap
- JXJT 8.4M
- ONVO 6.7M
- IPO Year
- JXJT 2012
- ONVO N/A
- Fundamental
- Price
- JXJT $0.83
- ONVO $0.35
- Analyst Decision
- JXJT
- ONVO
- Analyst Count
- JXJT 0
- ONVO 0
- Target Price
- JXJT N/A
- ONVO N/A
- AVG Volume (30 Days)
- JXJT 188.5K
- ONVO 271.7K
- Earning Date
- JXJT 12-31-2024
- ONVO 02-06-2025
- Dividend Yield
- JXJT N/A
- ONVO N/A
- EPS Growth
- JXJT N/A
- ONVO N/A
- EPS
- JXJT 0.48
- ONVO N/A
- Revenue
- JXJT $31,840,588.00
- ONVO $103,000.00
- Revenue This Year
- JXJT N/A
- ONVO $59.08
- Revenue Next Year
- JXJT N/A
- ONVO $18.24
- P/E Ratio
- JXJT $1.75
- ONVO N/A
- Revenue Growth
- JXJT N/A
- ONVO N/A
- 52 Week Low
- JXJT $0.80
- ONVO $0.32
- 52 Week High
- JXJT $8.51
- ONVO $1.74
- Technical
- Relative Strength Index (RSI)
- JXJT 26.93
- ONVO 35.52
- Support Level
- JXJT $0.80
- ONVO $0.34
- Resistance Level
- JXJT $1.26
- ONVO $0.43
- Average True Range (ATR)
- JXJT 0.11
- ONVO 0.05
- MACD
- JXJT -0.03
- ONVO -0.01
- Stochastic Oscillator
- JXJT 5.82
- ONVO 5.61
About JXJT JX Luxventure Limited
JX Luxventure Ltd is engaged in the tourism sector and supplying related products, including technology solutions, to business partners in China, both online and offline. The company operates in three segments Airline tickets and tourism services, Software Solutions for Tourism Cross-border operation, and Tourism Cross-border Merchandise. The majority of the group revenue is generated from Tourism products.
About ONVO Organovo Holdings Inc.
Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases.